Clinical trials: Non-Small-Cell Lung
Non-small Cell Lung Cancer Metastatic
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
Response rates. Changes in tumor blood flow.
- Trial name
- NA_00067809 (NCT01752023)
- Testing
- Cisplatin + Gemcitabine with SUBATM-itraconazole, Cisplatin + Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stage IV Non-Small Cell Lung Cancer
Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial
The core hypothesis to be tested is that the use of consolidative SBRT followed by maintenance chemotherapy in patients with less than or equal to 6 metastatic sites (primary + 5) will improve progression free survival (PFS)…
- Trial name
- NCT02045446
- Testing
- Stereotactic Body Radiation Therapy, Maintenance chemotherapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Carcinoma, Non-Small-Cell Lung
Palliative Thoracic Radiotherapy Plus BKM120
This study will test whether a drug called BKM120/buparlisib is a safe and effective treatment when given to lung cancer patients having radiotherapy treatment.
- Trial name
- BKM120 (NCT02128724)
- Testing
- BKM120
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Oxford
NSCLC, HNSCC
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
- Trial name
- TACTI-002 (NCT03625323)
- Testing
- eftilagimod alpha, pembrolizumab (KEYTRUDA®)
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- Immutep S.A.S.
Non Small Cell Lung Cancer
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
This is a randomized, controlled, double-blind, multicenter, phase III clinical study.
- Trial name
- NCT03849768
- Testing
- HS-10296, Gefitinib
- Where
- China
- Volunteers
- 429 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
This study is to determine that pembrolizumab is safe and tolerable at the selected dose for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with a performance status of 2. All patients will receive pembrolizumab.
- Trial name
- PePS2 (NCT02733159)
- Testing
- pembrolizumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Birmingham
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)
This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy.
- Trial name
- MERIT (NCT02774278)
- Testing
- Erlotinib
- Where
- 29 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 264 people
- Sponsor
- Hoffmann-La Roche
Oligometastatic Lung Adenocarcinoma
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
This study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. This study will also collect blood samples for research blood tests.
- Trial name
- NCT02450591
- Testing
- Erlotinib, Local Therapies
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer…
- Trial name
- NCT01268059
- Testing
- Carboplatin, Paclitaxel, MEDI-575
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 99 people
- Sponsor
- MedImmune LLC
Metastatic Non-squamous Non Small Cell Lung Cancer
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
This is a randomized, open-label, multicenter, phase II study to compare a triplet combination of CBP501, pemetrexed and cisplatin with pemetrexed/cisplatin when administered to patients with locally advanced (stage IIIB with…
- Trial name
- CBP08-02 (NCT00942825)
- Testing
- CBP501 + Cisplatin + Pemetrexed, Cisplatin + Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 195 people
- Sponsor
- CanBas Co. Ltd.
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
The purpose of this study was to evaluate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162 in advanced NSCLC patients carrying specific molecular alterations.
- Trial name
- NCT02276027
- Testing
- BYL719, INC280, LDK378
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Part A: To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of Xentuzumab (BI 836845) in combination with afatinib in patients with non-small cell lung cancer with progression following prior…
- Trial name
- NCT02191891
- Testing
- Xentuzumab, Afatinib
- Where
- 10 sites in Japan, Singapore and 2 more
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT03322540
- Testing
- Pembrolizumab, Epacadostat
- Where
- 101 sites in United States, Australia and 16 more
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Carcinoma, Non-Small-Cell Lung
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable…
- Trial name
- PACIFIC-5 (NCT03706690)
- Testing
- Durvalumab
- Where
- 87 sites in China, Hong Kong and 8 more
- Volunteers
- 407 people
- Sponsor
- AstraZeneca
Lung Cancer
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00795340
- Testing
- carboplatin, cediranib maleate, paclitaxel
- Where
- 19 sites in Brazil, Canada
- Volunteers
- 306 people
- Sponsor
- NCIC Clinical Trials Group
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Non Small Cell Lung Cancer, 4D CT
An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System
The goals of this clinical research are to evaluate the outcomes and tumor response for early stage non-small lung cancer (NSCLC) patients undergoing Stereotactic Body Radiation Therapy (SBRT) using four dimensional (4D) Positron…
- Trial name
- NCT02067858
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Steven Burton
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Non-small Cell Lung Cancer
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients.
- Trial name
- RADIANT (NCT00373425)
- Testing
- Erlotinib
- Where
- 295 sites in United States, Argentina and 17 more
- Volunteers
- 1,252 people
- Sponsor
- OSI Pharmaceuticals
Lung Cancer, Pulmonary Complications
Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy
RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer.
- Conditions
- Lung Cancer, Pulmonary Complications, Radiation Fibrosis
- Trial name
- NCT00077064
- Testing
- captopril
- Where
- 87 sites in United States
- Volunteers
- 81 people
- Sponsor
- Radiation Therapy Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.